{"id":229,"date":"2026-10-28T01:57:39","date_gmt":"2026-10-28T01:57:39","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=229"},"modified":"2026-10-28T01:57:39","modified_gmt":"2026-10-28T01:57:39","slug":"az137-macrocyclizing-bosutinib-into-a-potent-exquisitely-selective-chemical-probe-for-the-dark-kinase-hipk4-drug-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/az137-macrocyclizing-bosutinib-into-a-potent-exquisitely-selective-chemical-probe-for-the-dark-kinase-hipk4-drug-intelligence-dossier\/","title":{"rendered":"AZ137: Macrocyclizing Bosutinib into a Potent, Exquisitely Selective Chemical Probe for the Dark Kinase HIPK4 \u2014 Drug Intelligence Dossier"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">The problem: a dark kinase with no tools and no structure<\/h2>\n\n\n<p><strong>HIPK4<\/strong> sits in the unlit corner of the kinome. Knockout work implicates it in spermiogenesis (F-actin\/keratin-scaffolded sperm-head shaping) and in <strong>cutaneous squamous cell carcinoma<\/strong>, where it looks like a negative regulator of keratinocyte differentiation. But there has been <strong>no high-quality selective inhibitor<\/strong> and <strong>no deposited HIPK4 structure<\/strong> &#8212; the protein resists efficient expression and crystallization &#8212; so nobody could test whether its genetic phenotypes are pharmacologically addressable.<\/p>\n\n\n<h2 class=\"wp-block-heading\">The strategy: borrow bosutinib&#8217;s pharmacophore, delete its promiscuity<\/h2>\n\n\n<p>Bosutinib is a potent but famously <strong>broad-spectrum<\/strong> 3-cyanoquinoline kinase inhibitor. Across deposited co-crystals its bioactive conformation is highly conserved, with a flexible solvent-exposed tail doing little for binding. The Frankfurt\/SGC team (Zerva, Raig, Knapp, Hanke and co-workers, <em>J. Med. Chem.<\/em> 2026) made the elegant bet that <strong>macrocyclization<\/strong> &#8212; tethering the quinoline 6-O to the back-pocket aryl &#8212; would <strong>pre-organize<\/strong> the scaffold into fewer conformations and buy selectivity, following the lorlatinib\/pacritinib playbook.<\/p>\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1350\" height=\"300\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/hipk4_design_fig1e.png\" alt=\"\" class=\"wp-image-223\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/hipk4_design_fig1e.png 1350w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/hipk4_design_fig1e-300x67.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/hipk4_design_fig1e-1024x228.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/hipk4_design_fig1e-768x171.png 768w\" sizes=\"auto, (max-width: 1350px) 100vw, 1350px\" \/><figcaption class=\"wp-element-caption\">Design strategy: macrocyclization of flexible bosutinib into a conformationally restricted 3-cyanoquinoline, varying the linker, solvent-exposed R&#185; and back-pocket R&#178;. Reproduced under CC-BY 4.0 &#169; 2026 The Authors (ACS).<\/figcaption><\/figure>\n\n\n<h2 class=\"wp-block-heading\">The chemistry: build the core, then close the ring<\/h2>\n\n\n<p>The route assembles a <strong>4-chloro-6-hydroxy-7-methoxy-3-cyanoquinoline<\/strong> core (16), installs the back-pocket aniline by <strong>SNAr with a 2-aminophenol<\/strong> to give a linear bis-phenol, then performs the decisive step: an <strong>intramolecular double Williamson etherification<\/strong> with a short bis-electrophilic linker that stitches the two phenols into a macrocycle. Systematically walking the linker length, the solvent-exposed R&#185;, and the back-pocket R&#178; delivered <strong>AZ137 (28e)<\/strong> &#8212; the Ar&#8310; \/ diethylene-glycol-tether macrocycle.<\/p>\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"2392\" height=\"1286\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/az137_scheme.png\" alt=\"\" class=\"wp-image-224\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/az137_scheme.png 2392w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/az137_scheme-300x161.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/az137_scheme-1024x551.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/az137_scheme-768x413.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/az137_scheme-1536x826.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/az137_scheme-2048x1101.png 2048w\" sizes=\"auto, (max-width: 2392px) 100vw, 2392px\" \/><figcaption class=\"wp-element-caption\">Redrawn route to AZ137: 3-cyanoquinoline core &#8594; SNAr with a 2-aminophenol &#8594; intramolecular double etherification (macrocyclization). Redrawn by Astinova Bio Labs from Zerva, Raig et al., J. Med. Chem. 2026, 69, 20616 (Scheme 2).<\/figcaption><\/figure>\n\n\n<h2 class=\"wp-block-heading\">The structural read-out: a preorganized macrocycle in a surrogate pocket<\/h2>\n\n\n<p>With no HIPK4 structure available, the team crystallized their macrocycles in <strong>CLK3<\/strong>, the closest tractable surrogate (newly deposited as PDB 29MP\/29MO), and confirmed a <strong>preorganized binding conformation<\/strong> consistent with an AlphaFold HIPK4 model. Shown here is a macrocyclic inhibitor bound in CLK3 (PDB 6Z51) &#8212; the same kinase used as the structural proxy &#8212; threading its ether-linked ring past the hinge region (near <strong>Leu290<\/strong>, one of the few residues that differ from HIPK4&#8217;s Met143).<\/p>\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"945\" height=\"789\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/clk3_binding_6z51.png\" alt=\"\" class=\"wp-image-225\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/clk3_binding_6z51.png 945w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/clk3_binding_6z51-300x250.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/clk3_binding_6z51-768x641.png 768w\" sizes=\"auto, (max-width: 945px) 100vw, 945px\" \/><figcaption class=\"wp-element-caption\">A macrocyclic inhibitor bound in CLK3 (PDB 6Z51), the surrogate kinase used to crystallize this series; HIPK4 itself has no deposited structure. Rendered by Astinova Bio Labs (3Dmol.js).<\/figcaption><\/figure>\n\n\n<h2 class=\"wp-block-heading\">The lead: AZ137 (28e)<\/h2>\n\n\n<ul class=\"wp-block-list\"><li><strong>HIPK4 IC<sub>50<\/sub> = 11 nM; cellular EC<sub>50<\/sub> = 76 nM<\/strong><\/li><li><strong>Exceptional selectivity<\/strong> across three orthogonal panels &#8212; in the Eurofins scanMAX 468-kinase screen at 100 nM, HIPK4 (PoC 7.3%) was essentially the only genuine hit; <strong>30&#8211;80&#215; over the nearest CLK isoforms<\/strong><\/li><li><strong>High solubility, no detectable cytotoxicity<\/strong><\/li><li>Cellular target engagement confirmed via <strong>HIPK4-dependent F-actin remodeling<\/strong><\/li><li>Shipped as a <strong>probe set<\/strong> with a structurally matched <strong>negative-control compound<\/strong> (&gt;100&#215; less active)<\/li><\/ul>\n\n\n<h2 class=\"wp-block-heading\">Why it matters<\/h2>\n\n\n<ul class=\"wp-block-list\"><li><strong>First high-quality, selective HIPK4 chemical probe<\/strong> &#8212; the reagent needed to de-orphanize a dark kinase and test its SCC\/reproductive biology pharmacologically.<\/li><li>A clean demonstration that <strong>macrocyclization is a selectivity tool<\/strong>, not just a PK trick, for the tightly conserved CMGC group.<\/li><li>Delivering a probe <strong>without a target crystal structure<\/strong> &#8212; leaning on a surrogate kinase plus an AlphaFold model &#8212; is an increasingly common, and underrated, medicinal-chemistry capability.<\/li><\/ul>\n\n\n<p><strong>Reference &amp; image credit:<\/strong> Zerva, A.; Raig, N. D. et al. &#8220;Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib Leads to Potent and Selective Quinoline-Based HIPK4 Inhibitor AZ137.&#8221; <em>J. Med. Chem.<\/em> <strong>2026<\/strong>, <em>69<\/em>, 20616&#8211;20638. DOI: 10.1021\/acs.jmedchem.6c01320. Design figure reproduced under a <strong>CC-BY 4.0<\/strong> license &#169; 2026 The Authors, published by the American Chemical Society. Synthesis scheme redrawn and binding-site figure (CLK3 surrogate, PDB 6Z51) rendered by Astinova Bio Labs.<\/p>\n\n\n<p><em>Macrocyclization, conformational restriction, original route design, structure-based rationale &#8212; this is the work Astinova Bio Labs does for discovery partners. <a href=\"https:\/\/astinovabiolabs.com\/\">Talk to us<\/a> about your scaffold.<\/em><\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>Macrocyclizing flexible bosutinib locks its 3-cyanoquinoline into AZ137 (HIPK4 IC50 11 nM) \u2014 a first-in-class selective chemical probe for a dark kinase, delivered without a target crystal structure. With a redrawn macrocyclization route and a CLK3-surrogate binding render.<\/p>\n","protected":false},"author":1,"featured_media":223,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[63,58,62,59,61,60,37,64],"class_list":["post-229","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-chemistry","tag-bosutinib","tag-chemical-probe","tag-dark-kinome","tag-hipk4","tag-kinase-inhibitor","tag-macrocyclization","tag-oncology","tag-selectivity"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=229"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/229\/revisions"}],"predecessor-version":[{"id":231,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/229\/revisions\/231"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/223"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}